Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Scotland says no to prostate cancer drug Abiraterone

Patients with advanced prostate cancer in Scotland will not get access to a new drug which can extend their lives by more than three months. Prostate cancer is the most common cancer to affect men and the second most common cause of death.

13 Mar 2012

Cancer Research UK disappointed over SMC ruling against advanced prostate cancer drug

Cancer Research UK is extremely disappointed that the advanced prostate cancer drug, abiraterone, has been ruled too expensive for routine use by the Scottish Medicines Consortium (SMC).

12 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

Circumcision may decrease risk of prostate cancer

A new analysis led by researchers at Fred Hutchinson Cancer Research Center has found that circumcision before a male's first sexual intercourse may help protect against prostate cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that circumcision can hinder infection and inflammation that may lead to this malignancy.

12 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

Obesity, medical distrust contribute to high rates of prostate cancer in Louisiana

Factors such as increased risk for African-Americans, obesity and medical distrust contribute to high rates of prostate cancer in Louisiana. Louisiana has the fourth highest prostate cancer death rate in the country and the sixth highest incidence rate, according to data from North American Association of Central Cancer Registries, National Cancer Institute and the Centers for Disease Control and Prevention.

9 Mar 2012

Elekta Clarity 3D system transforms prostate radiotherapy at UHG

Soft tissue imaging with 3D ultrasound both at therapy simulation and just before treatment has transformed prostate radiotherapy at University Hospital Galway.

From Elekta 9 Mar 2012

DC has highest prostate cancer incidence and death rate

Increased risk for African-Americans, medical distrust and negative attitudes toward testing contribute to high rates of prostate cancer in the District of Columbia. DC has the highest prostate cancer incidence rate and death rate in the country, according to data from North American Association of Central Cancer Registries, National Cancer Institute and the Centers for Disease Control and Prevention.

9 Mar 2012

Bellicum raises $20M in Series B financing

Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Sleeping pills may raise risk of death: Study

According to a U.S. study, people who take certain prescription sleeping pills even once in a while may be up to five times more susceptible to early death. In the U.S., an estimated six per cent to 10 per cent of adults used the drugs in 2010.

29 Feb 2012

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 28 February 2012 to review the Group's results for 2011, published today.

29 Feb 2012

Two-target approach may effectively stop pancreatic cancer metastasis

Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found—work that may improve the effectiveness of combination treatments that include drugs like Avastin.

27 Feb 2012

Viewpoints: Elizabeth Warren on contraception mandate, comparison shopping for drugs, 'dismantling' Illinois

In this Kaiser Health News Different Takes feature, The University Of Maryland's Dr. E. Albert Reece and The Heritage Foundation's Stuart Butler discuss how health enterprise zones, a new take on an old economic development idea, might be used to improve the health of the state's minority populations (2/23). Read the commentaries by Reece and Butler.

24 Feb 2012

UCSF: 1-2 punch blocks tumor growth, invasion and metastasis

Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found-work that may improve the effectiveness of combination treatments that include drugs like Avastin.

24 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

European Urology to launch two new Resource Centres

European Urology, the official peer-reviewed journal of the EAU, is to launch two new Resource Centres that can be accessed from www.europeanurology.com. Both resource centres aim to provide information around a specific topic in urology.

24 Feb 2012

Scientists identify specific mechanisms by which vitamin D inhibits inflammation

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling.

24 Feb 2012

Researchers discover how mTOR protein leads to cancer metastasis

Uncovering the network of genes regulated by a crucial molecule involved in cancer called mTOR, which controls protein production inside cells, researchers at the University of California, San Francisco (UCSF) have discovered how a protein "master regulator" goes awry, leading to metastasis, the fatal step of cancer.

23 Feb 2012